Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib dose-escalation with thoracic radiotherapy with or without cisplatin in locally advanced non-small cell lung cancer
NL-OMON39751Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of olaparib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Dose-limiting toxicities. Started Jun 2012; status: recruiting.
02
Drugs
olaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON39751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39751.